Zohydro

Zohydro ER is an extended-release formulation of hydrocodone bitartrate, a semi-synthetic opioid analgesic. It is marketed as a single-ingredient hydrocodone product in hard gelatin capsules and contains no acetaminophen or other analgesics. Zohydro ER is intended for the management of moderate to severe chronic pain that requires around-the-clock opioid treatment for an extended period and for which alternative treatments are inadequate or not tolerated.

The medication is taken orally and designed to release hydrocodone over an extended period, providing long-lasting pain relief. It is available in multiple strengths, with dosing and duration determined by a clinician based on the patient’s prior opioid exposure, response, and risk factors. Because it is a potent opioid, it carries risks common to opioid therapy, including the potential for misuse, dependence, tolerance, and life-threatening respiratory depression. Common adverse effects include constipation, nausea, vomiting, dizziness, and somnolence. Serious risks increase when used with alcohol, benzodiazepines, or other CNS depressants and when the drug is used outside prescribed guidelines.

Regulatory status places Zohydro ER as a Schedule II controlled substance in the United States, reflecting its potential for abuse and dependence. Its development and market introduction occurred during debates about the safety of extended-release hydrocodone products, particularly those not combined with acetaminophen. Zohydro ER remains part of broader discussions on opioid prescribing, safety, and abuse prevention.